Clinical Trial Update: Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating pazopanib plus lapatinib versus lapatinib alone and pazopanib alone in metastatic cervical cancer; results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Tykerb (lapatinib)
• Votrient (Pazopanib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Uterine Cervix, Metastatic Cervical Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-03-14